Our News

Affinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026

FDA Grants Orphan Drug Designation to Affinia Therapeutics’ AFTX-201 for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)

ASGCT 2026: AFTX-201: A Novel Investigational AAV Gene Therapy for the Treatment of BAG3-Associated Dilated Cardiomyopathy

ASGCT 2026: Process Development, Technology Transfer, Clinical Manufacturing, and Process Characterization of AFTX-201, an Investigational New Medicine for the Treatment of BAG3-Associated Dilated Cardiomyopathy

ASGCT 2026: Study Design of a Phase 1/2 Multicenter, Open-Label, Dose-Exploration and Dose-Expansion Trial of AFTX-201 in Adults With BCL-2 Associated Athanogene 3 (BAG3) Mutation-Associated Dilated Cardiomyopathy (UPBEAT Trial)

ASGCT 2026: Development, Technology Transfer, and Qualification of Product-Specific Methods for AFTX-201, an Investigational New Medicine for the Treatment of BAG3-Associated Dilated Cardiomyopathy

Discover what it’s like to be an Affinian

Changing the world for patients – powered by science